ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "rheumatoid arthritis"

  • Abstract Number: 1370 • ACR Convergence 2024

    Upadacitinib vs TNFi and Other JAKi Treatment Outcomes in Australian Rheumatoid Arthritis Patients: Descriptive Comparison of Persistence and Effectiveness Using the OPAL Dataset

    Sabina Ciciriello1, Peter Youssef2, Talib Tahir3, Tegan Smith4, Catherine O'Sullivan4, Joanna Leadbetter5, Belinda Butcher5, Miriam Calao6, Nicole Walsh6 and Geoffrey Littlejohn7, 1The University of Melbourne, Melbourne, Victoria, Australia, 2Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia, 3Coburg Rheumatology Service, Coburg, Victoria, Australia, 4OPAL Rheumatology Ltd, Geelong, Victoria, Australia, 5WriteSource Medical Pty Ltd, Lane Cove, New South Wales, Australia, 6AbbVie Pty Ltd, Mascot, New South Wales, Australia, 7Monash University, Clayton, Victoria, Australia

    Background/Purpose: To descriptively compare treatment patterns, persistence and effectiveness of upadacitinib (UPA), other JAK inhibitors (JAKi) and tumour necrosis factor inhibitors (TNFi) in rheumatoid arthritis…
  • Abstract Number: 1387 • ACR Convergence 2024

    Olokizumab Effect on Chronic Pain in Rheumatoid Arthritis: Results of the Observational Study

    Andrey Karateev1, Sofia Kuzkina2, Galym Togizbayev3, Elena Polishuk1, Ekaterina Filatova1, Vera Amirdzhanova1, Victoria Khlaboshchina1, Natalia Lapkina4, Andrey Baranov4 and Alexander Lila5, 1V.A. Nasonova Research Institute of Rheumatology, Moscow, Russia, 2R-Pharm, Moscow, Russia, 3Kazakh National Medical University named after Asfendiyarov S, Almaty, Kazakhstan, 4Yaroslavl State Medical University, Yaroslavl, Russia, 5Russian Medical Academy of Continuous Professional Education of the Ministry of Healthcare of the Russian Federation, Moscow, Russia

    Background/Purpose: To evaluate efficacy and safety of olokizumab (interleukin-6 inhibitor) in RA patients with special attention to chronic pain and a signs of central sensitization.Methods:…
  • Abstract Number: 1405 • ACR Convergence 2024

    Perceived Healthcare Discrimination Among Individuals with Musculoskeletal Conditions: A Retrospective Cross-Sectional Analysis

    Titilayo Adeniran1, Bertilia Trieu2, Sandra Goldsmith1 and Laura Robbins1, 1Hospital for Special Surgery (HSS), New York, NY, 2Hospital for Special Surgery, New York, NY

    Background/Purpose: Musculoskeletal conditions, including osteoarthritis (OA), osteoporosis (OP), rheumatoid arthritis (RA), and chronic pain, significantly burden individuals' health and well-being. These conditions often lead to…
  • Abstract Number: 1682 • ACR Convergence 2024

    Early Development of Ocadusertib, a Selective Receptor-Interacting Serine/Threonine-Protein Kinase 1 Inhibitor

    Eric Hanson1, Daniel Dairaghi1, Andrew C. Vendel1, Jonathan Sims1, Yasushi Takita1, Lucy Yan2, Andrew Chow2, Simon Shaw2 and esteban S. Masuda2, 1Eli Lilly and Company, Indianapolis, IN, 2Rigel Pharmaceuticals, San Francisco

    Background/Purpose: Receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitors are under investigation in chronic inflammatory diseases such as rheumatoid arthritis, inflammatory bowel disease, and psoriasis. Ocadusertib (LY3871801;…
  • Abstract Number: 1846 • ACR Convergence 2024

    Citrullinated Vimentin-reactive Immune-regulatory CD4+CD39+TIGIThi T Cells Expand During Drug Free Remission in HLA-DR Shared-epitope+ ACPA+ Rheumatoid Arthritis

    Amy Anderson1, Henrique de Paula Lemos1, Hendrik Nel2, Sofia Sorbet Santiago1, Fiona Rayner3, Abbie Degnan1, Imogen Wilson1, Julie Diboll1, Jasmine Sim1, Andrew Melville4, Stefan Siebert4, Iain McInnes5, Carl Goodyear4, Catharien Hilkens1, Andrew Filer6, Karim Raza6, Christopher Buckley7, Hugh Reid8, Kenneth Baker1, Arthur Pratt3, Jamie Rossjohn8, Ranjeny Thomas9 and John Isaacs1, 1Translational and Clinical Research Institute, NIHR Newcastle Biomedical Research Centre, Newcastle University and The Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom, 2Frazer Institute, The University of Queensland, Translational Research Institute, Brisbane, Australia, 3Translational and Clinical Research Institute, NIHR Newcastle Biomedical Research Centre, Newcastle University and The Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, England, United Kingdom, 4School of Infection and Immunity, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom, 5University of Glasgow, College of Medical Veterinary and Life Sciences, Glasgow, United Kingdom, 6Rheumatology Research Group, Institute for Inflammation and Ageing, NIHR Birmingham Biomedical Research Center and Clinical Research Facility, University of Birmingham, Birmingham, United Kingdom, 7Kennedy Institute of Rheumatology, University of Oxford, Oxford, United Kingdom, 8Department of Biochemistry and Molecular Biology, School of Biomedical Sciences, Monash University, Clayton, Victoria, Australia, 9University of Queensland, Brisbane, Australia

    Background/Purpose: There is a need for immunotherapy that sustains symptom remission without ongoing need for disease modifying drugs (DMARDs). In a phase 1b trial of…
  • Abstract Number: 1905 • ACR Convergence 2024

    Combining Three Peripheral Biomarkers to Stratify Rheumatoid Arthritis-Associated Interstitial Lung Disease Risk

    Bryant England1, Austin Wheeler1, Brent Luedders1, Michael Duryee1, Halie Frideres2, Katherine Wysham3, grant Cannon4, Gary Kunkel5, Dana Ascherman6, Paul Monach7, Gail Kerr8, Andreas Reimold9, Joshua Baker10, Geoffrey Thiele1 and Ted Mikuls1, 1University of Nebraska Medical Center, Omaha, NE, 2UNMC Department of Rheumatology, Omaha, NE, 3VA PUGET SOUND/UNIVERSITY OF WASHINGTON, Seattle, WA, 4University of Utah and Salt Lake City VA, Salt Lake City, UT, 5University of Utah and George E Wahlen VAMC, Salt Lake City, UT, 6Division of Rheumatology and Clinical Immunology, University of Pittsburgh Medical Center, Pittsburgh, PA, 7VA Boston Healthcare System, Boston, MA, 8Washington DC VAMC/Georgetown and Howard Universities, Washington, DC, 9Dallas VA Medical Center, Dallas, TX, 10Department of Medicine, Perelman School of Medicine University of Pennsylvania, Philadelphia, PA

    Background/Purpose: Several peripheral biomarkers for RA-associated interstitial lung disease (RA-ILD) have been evaluated to enhance early RA-ILD identification. The MUC5B rs35705950 promoter variant, matrix metalloproteinase-7…
  • Abstract Number: 2121 • ACR Convergence 2024

    Increased Fracture Rates in Patients Continuing Methotrexate After Methotrexate-associated Lower Limb Insufficiency Fractures: A Retrospective Follow-up Study

    Roba Ghossan1, OLIVIER FOGEL2, Christian Roux1 and Karine Briot1, 1COCHIN HOSPITAL, PARIS, France, 2AP-HP, Paris, France

    Background/Purpose: Spontaneous  lower limb insufficiency fractures (LLIF) described under prolonged exposure to low-dose methotrexate are often bilateral, multiple, and recurrent. They share a common pathognomonic…
  • Abstract Number: 2217 • ACR Convergence 2024

    A Significant Alteration in Circulating Endocannabinoid Levels in Rheumatoid Arthritis and Fibromyalgia Syndrome Patients and Its Correlation with Diseases Severity

    Gilad Halpert1, Eri Govrin2, Boris Gilburd3, Shlomo Segev3, Omer Gendelman4, Abdulla Watad5, Yehuda Shoenfeld6, David Meiri7 and Howard Amital8, 1CAHIM SHEBA MEDICAL CENTER, Tel Hashomer, Israel, 2Sheba Medical Center, Sdot Micha, Israel, 3Sheba Medical Center, Ramat-Gan, Israel, 4Sheba Medical Center, Ramat Gan, Israel, 5Tel Hashomer Medical Center, Ramat Gan, Israel, 6sheba medical center , Israel, Ramat Gan, Israel, 7Technion-Israel Institute of Technology, Haifa, Israel, 8Sheba Medical Center, Tel-Hashomer, Israel, Ramat Gan, Israel

    Background/Purpose: Accumulating evidence suggests that medical cannabis therapy might have beneficial therapeutic effects in the fibromyalgia syndrome (FMS) and in difficult-to-treat rheumatoid arthritis (RA) patients.…
  • Abstract Number: 2234 • ACR Convergence 2024

    Pulmonary Damage Biomarkers and Progression of Rheumatoid Arthritis-associated Interstitial Lung Disease in a Prospective Longitudinal Cohort

    Sung Hae Chang1, Yong-Beom Park2, Gregory McDermott3, Misti Paudel4, Keigo Hayashi3, You-Jung Ha5, Jeong Seok Lee6, Min Uk Kim7, Chan Ho Park8, Sang Wan Chung9, Ji-Won Kim10, Jang Woo Ha11, Sung Won Lee12, Eun Ha Kang5, Yeon-Ah Lee13, Jung-Yoon Choe14, Eun Young Lee15 and Jeffrey Sparks16, and the KOrean Rheumatoid Arthritis Interstitial Lung Disease (KORAIL) group, 1Brigham and Women's Hospital/Soonchunhyang University, College of Medicine, Boston, MA, 2Yonsei University College of Medicine, Seoul, Republic of Korea, 3Brigham and Women's Hospital, Brookline, MA, 4Brigham and Women's Hospital, Division of Rheumatology, Inflammation, and Immunity, Boston, MA, 5Seoul National University Bundang Hospital, Seongnam, South Korea, 6Korea Advanced Institute of Science and Technology, KAIST,, Daejeon, Republic of Korea, 7SMG-SNU Boramae Medical Center, Seoul, Republic of Korea, 8Soonchunhyang University College of Medicine,, Cheonan-si, Republic of Korea, 9Kyung Hee University Hospital, Seoul, Republic of Korea, 10Daegu Catholic University School of Medicine, Nam-gu, Daegu, South Korea, 11Yonsei university college of medicine, Seodaemun-gu, Seoul, South Korea, 12Soonchunhyang University Cheonan Hospital, Seoul, South Korea, 13Kyung Hee University Hospital, Seoul, South Korea, 14Catholic University of Daegu School of Medicine, Daegu, Republic of Korea, 153Division of Rheumatology, Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea, 16Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA, Boston, MA

    Background/Purpose: RA-associated interstitial lung disease (ILD) is a heterogeneous disease with a chronic course and potential for flares. Serum biomarkers are needed to identify those…
  • Abstract Number: 2251 • ACR Convergence 2024

    Stress-Related Neural Activity Measured with FDG-PET/CT Is Associated with Articular Disease Activity, Systemic Inflammation, and Treatment-associated Change in Arterial Inflammation in Rheumatoid Arthritis

    Jon Giles1, Joan Bathon2, Katherine Liao3, Pamela Rist4, Shady Abohashem5, Michael Osborne5, Giovani Civieri5, Zahi Fayad6, Daniel Solomon3 and Ahmed Tawakol7, 1Cedars Sinai Medical Center, Los Angeles, CA, 2Columbia University, New York, NY, 3Brigham and Women's Hospital, Boston, MA, 4Brigham & Women's Hospital/Harvard University, Boston, MA, 5Massachusetts General Hospital/Harvard University, Boston, MA, 6Mount Sinai Medical Center, New York, NY, 7Massachusetts General Hospital/Harvard Medical School, Boston, MA

    Background/Purpose: The amygdala, a limbic structure of the brain’s salience network, links chronic external stressors with downstream effects on the HPA axis and hematopoietic tissues…
  • Abstract Number: 2272 • ACR Convergence 2024

    Evolution of Methotrexate and Prednisone Use in the Era of Biologic Therapy: 15-Year Findings from a Large Rheumatoid Arthritis Registry

    Dimitrios Pappas1, George Reed2, Kevin kane3, Michael Weinblatt4 and Joel Kremer5, 1CorEvitas, New York, NY, 2University of Massachusetts Chan Medical School, Worcester, MA, 3University of Massachusetts Lowell, Lowell, MA, 4Brigham and Women's Hospital/ Harvard Medical School, Waban, MA, 5The Corrona Research Foundation, Delray Beach, FL

    Background/Purpose: Methotrexate (MTX) continues to be the cornerstone therapy in the treatment of rheumatoid arthritis (RA) and is usually the first conventional synthetic (cs) DMARD…
  • Abstract Number: 2531 • ACR Convergence 2024

    CRISPR Deletion Screen in Fibroblasts Identifies Novel Regulators of Inflammation

    Alisa Mueller1, Suppawat Kongthong2, Angela Zou3, Gerald Watts4, Cassandra Murphy2, Hung Nguyen2, Jacqueline Perrigoue5, Mathew Chamberlain5, Kevin Wei6, Soumya Raychaudhuri2 and Michael Brenner7, 1Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 2Brigham and Women's Hospital, Boston, MA, 3Harvard Medical School, Boston, MA, 4Harvard Medical School, Brookline, MA, 5Johnson & Johnson, Spring House, PA, 6Brigham and Women's Hospital at Harvard Medical School, Boston, MA, 7Brigham and Women's Hospital, Harvard Medical School, Newton, MA

    Background/Purpose: In rheumatoid arthritis (RA), synovial fibroblasts adopt an inflammatory phenotype that catalyzes pathogenic synovial hyperplasia and ultimately bone and cartilage destruction. However, identifying therapeutic…
  • Abstract Number: 2606 • ACR Convergence 2024

    Changes in Long-term GC Use Among Older Adults After New Diagnosis of Late-onset Rheumatoid Arthritis

    Jiha Lee1, Jonathan Martindale1, Beth Wallace2, Namrata Singh3, Una Makris4 and Julie Bynum1, 1University of Michigan, Ann Arbor, MI, 2Michigan Medicine, VA Ann Arbor Healthcare System, Ann Arbor, MI, 3University of Washington, Bellevue, WA, 4UT Southwestern Medical Center and Dallas VA, Dallas, TX

    Background/Purpose: Older adults with late-onset rheumatoid arthritis (LORA) receive less disease-modifying anti-rheumatic drugs (DMARDs), which is the standard of care. In contrast, long-term glucocorticoid (GC)…
  • Abstract Number: PP08 • ACR Convergence 2024

    Whispers of Resilience: Navigating Life with Rheumatism

    Vinchelle Hardison and Vinchelle Hardison, Nationwide Children's Hospital, Columbus, OH

    Background/Purpose: “What’s wrong with me mom? Why am I always slow and hurting? Why can’t I play without being in pain like the other kids?”…
  • Abstract Number: 0035 • ACR Convergence 2024

    Anti-CCP Generation in the Female Genital Tract Is Increased During the Postpartum Period in Women Without RA

    Daniele Marcy1, Ashley Visser2, Claudia Lugo2, Kristin Sturm2 and Kristen Demoruelle3, 1University of Colorado Anschutz Medical Campus, Northglenn, CO, 2University of Colorado Anschutz Medical Campus, Aurora, CO, 3University of Colorado Anschutz Medical Campus, Golden, CO

    Background/Purpose: It is well established that women develop RA approximately three times more often than men. In addition, several risk factors for RA uniquely effect…
  • « Previous Page
  • 1
  • …
  • 27
  • 28
  • 29
  • 30
  • 31
  • …
  • 188
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology